# Regeneron Pharmaceuticals, Inc. – Consensus ‘buy’ rating and 47.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/regeneron-pharmaceuticals-inc-consensus-buy-rating-and-47-5-upside-potential/4121184562
- Published: 2025-01-22T13:44:43+00:00
- Author: Charlotte Edwards

**Regeneron Pharmaceuticals, Inc.** with ticker code (REGN) now have 25 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The range
between the high target price and low target price is between $1,230.00 and $565.00
with the average target price sitting at $1,005.61. Given that the stocks previous
close was at $681.58 and the analysts are correct then we can expect a percentage
increase in value of 47.5%. It’s also worth noting that there is a 50 day moving
average of $743.42 and the 200 day moving average is $958.08. The market cap for
the company is 75.58B. The current share price for the company is: $687.80 USD

 The potential market cap would be $111,515,479,986 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 17.01, revenue per share of $128.69
and a 7.41% return on assets.

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers,
invents, develops, manufactures, and commercializes medicines for serious diseases.
Its commercialized medicines and product candidates in development are designed 
to help patients with eye diseases, allergic and inflammatory diseases, cancer, 
cardiovascular and metabolic diseases, pain, hematologic conditions, infectious 
diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection,
Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab)
Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza(
evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection,
ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept)
Injection for Intravenous Infusion. The Company also provides Expresse service assurance
and CloudCheck WiFi experience management solutions.

Share on:
